Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A1EWVY8
Wed, 01.02.2023       Formycon AG
DE000A1EWVY8

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.Publication of ins [ … ]
Technical analysis
To the publication
Wed, 01.02.2023       Formycon AG
DE000A1EWVY8

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.Publication of ins [ … ]
Technical analysis
To the publication
Mon, 09.01.2023       Formycon AG
DE000A1EWVY8

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // January 9, 2023 Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States Munich – Klinge Bi [ … ]
Technical analysis
To the publication
Fri, 26.08.2022       Formycon AG
DE000A1EWVY8

  Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 26, 2022 Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2 Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the European Commission (“EC”) today has granted marketi [ … ]
Technical analysis
To the publication
Fri, 26.08.2022       Formycon AG
DE000A1EWVY8

  Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 26, 2022 Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2 Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the European Commission (“EC”) today has granted marketi [ … ]
Technical analysis
To the publication
Wed, 03.08.2022       Formycon AG
DE000A1EWVY8

    Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 3, 2022 Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2 Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the U.S. Food  [ … ]
Technical analysis
To the publication
Wed, 03.08.2022       Formycon AG
DE000A1EWVY8

    Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 3, 2022 Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2 Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the U.S. Food  [ … ]
Technical analysis
To the publication
Fri, 24.06.2022       Formycon AG
DE000A1EWVY8

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 24, 2022 FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") announce that  [ … ]
Technical analysis
To the publication
Thu, 19.05.2022       Formycon AG
DE000A1EWVY8

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // May 19, 2022 Formycon announces changes to its Executive Board Munich – Today and effective July 1, 2022, the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") appointed Dr. Stefan Glombitza, wh [ … ]
Technical analysis
To the publication
Tue, 17.05.2022       Formycon AG
DE000A1EWVY8

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // May 17, 2022 FYB201, Formycon's Biosimilar for Lucentis®1 achieves Marketing Authorization in United Kingdom Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce, that tod [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.